Akero Therapeutics Inc Stock
Price
Target price
€48.21
€48.21
-1.180%
-0.57
-1.180%
€65.05
17.06.25 / Tradegate
WKN: A2PLNP / Symbol: AKRO / Name: Akero Therapeutics / Stock / Biotechnology & Medical Research / Small Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Akero Therapeutics Inc Stock
A loss of -1.180% shows a downward development for Akero Therapeutics Inc.
Akero Therapeutics Inc is currently one of the favorites of our community with 14 Buy predictions and no Sell predictions.
As a result the target price of 65 € shows a positive potential of 34.83% compared to the current price of 48.21 € for Akero Therapeutics Inc.
For the coming years our community has positive and negative things to say abot the Akero Therapeutics Inc stock. Criterium "Revenue growth" gathered the most positive votes but regarding "Worthwhile Investment for the next years" there were negative voices in the community.
Pros and Cons of Akero Therapeutics Inc in the next few years
Pros
?
W********* I********* f** t** n*** y****
?
S********** s********
?
M***** P*******
Cons
?
B****
?
G***** c******* t* c**********
?
C******** o* t** e**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Akero Therapeutics Inc vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Akero Therapeutics Inc | -1.180% | 1.006% | 38.217% | 126.020% | 79.754% | - | - |
| Krystal Biotech | 0.840% | -6.441% | -3.286% | -31.623% | -25.558% | 113.774% | - |
| Ardelyx Inc. | -1.800% | -5.292% | -10.932% | -47.221% | -37.644% | 490.614% | -47.077% |
| Evolus Inc | -2.370% | -0.588% | -1.744% | -17.157% | -19.524% | -22.477% | 87.778% |
Comments
Akero Therapeutics, Inc. (NASDAQ: AKRO) had its price target raised by analysts at Bank of America Co. from $63.00 to $64.00. They now have a "buy" rating on the stock.
Show more
Ratings data for AKRO provided by MarketBeat
Akero Therapeutics, Inc. (NASDAQ: AKRO) had its price target lowered by analysts at Citigroup Inc. from $80.00 to $78.00. They now have a "buy" rating on the stock.
Show more
Ratings data for AKRO provided by MarketBeat
Akero Therapeutics, Inc. (NASDAQ: AKRO) had its "overweight" rating re-affirmed by analysts at Morgan Stanley.
Show more
Ratings data for AKRO provided by MarketBeat
News
Akero Therapeutics Stock: Breakthrough Data Strengthens Market Position
Akero Therapeutics has released compelling 96-week data from its Phase-IIb SYMMETRY study of Efruxifermin (EFX) for advanced liver cirrhosis, marking a significant turnaround for the biotechnology
